Competing Ligand | |||||||
---|---|---|---|---|---|---|---|
Construct | CCL3 | TAK-779 | |||||
IC50 | Log IC50 | IC50 | Log IC50 | ||||
nM | M | nM | M | ||||
WT CCR5 | 28.12 | −7.55 ± 0.16 | 7.12 | −8.15 ± 0.10 | |||
W86A2.60 | 32.26 | −7.51 ± 0.29 | N.O.D. | N.O.D. | |||
Y108A3.32 | 29.51 | −7.53 ± 0.51 | N.O.D. | N.O.D. | |||
F109A3.33 | 12.44 | −7.91 ± 0.24 | 14.45 | −7.84 ± 0.19 | |||
E283Q7.39 | 52.84 | −7.28 ± 0.56 | 11.59 | −7.94 ± 0.16 |
N.O.D., no observable displacement (i.e., at a 1000-fold excess of unlabeled ligand, less than 50% displacement of 125I-CCL3 was observed).